Volasertib trihydrochloride is a small molecule inhibitor primarily targeting the polo-like kinase 1 (PLK1), which plays a crucial role in cell division and proliferation. This compound is characterized by its ability to disrupt mitotic processes, making it a candidate for cancer therapy, particularly in hematological malignancies and solid tumors. As a trihydrochloride salt, it is highly soluble in water, which enhances its bioavailability for therapeutic applications. The molecular structure of Volasertib includes a complex arrangement of aromatic and heterocyclic rings, contributing to its potency and specificity as a kinase inhibitor. In preclinical studies, it has demonstrated significant antitumor activity, leading to its evaluation in clinical trials. Safety and efficacy profiles are continuously assessed to determine optimal dosing regimens and potential side effects. Overall, Volasertib trihydrochloride represents a promising avenue in targeted cancer treatment, reflecting the ongoing advancements in precision medicine.

Volasertib trihydrochloride

946161-17-7: Volasertib trihydrochloride is a small molecule inhibitor primarily targeting the polo-like kinase 1 (PLK1), which plays a crucial role in cell division and proliferation. This compound is characterized by its ability to disrupt mitotic processes, making it a candidate for cancer therapy, particularly in hematological malignancies and solid tumors. As a trihydrochloride salt, it is highly soluble in water, which enhances its bioavailability for therapeutic applications. The molecular structure of Volasertib includes a complex arrangement of aromatic and heterocyclic rings, contributing to its potency and specificity as a kinase inhibitor. In preclinical studies, it has demonstrated significant antitumor activity, leading to its evaluation in clinical trials. Safety and efficacy profiles are continuously assessed to determine optimal dosing regimens and potential side effects. Overall, Volasertib trihydrochloride represents a promising avenue in targeted cancer treatment, reflecting the ongoing advancements in precision medicine.

<p>Volasertib (BI 6727), a potent PLK1 inhibitor (IC50: 0.87 nM), also targets PLK2 and PLK3, causes mitotic arrest, apoptosis, and anticancer effects.</p>

CAS 946161-17-7

Volasertib trihydrochloride

Volasertib trihydrochloride

Ref: TM-T41100